Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Articles

Erratum

Erratum to ‘Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial’ [Clin Mol Hepatol 2024;30:807-823]

Clinical and Molecular Hepatology 2025;31(2):669-670.
Published online: February 27, 2025

1Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea

2Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Korea

3Metabolic Regulation Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, Korea

4Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

5Department of Surgery, Korea University Guro Hospital, Seoul, Korea

6Department of Obstetrics and Gynecology, Kyung Hee University Hospital at Gangdong, Seoul, Korea

7Department of Medicine, Graduate School, Kyung Hee University, Seoul, Korea

8Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

9Department of Pathology, Yonsei University College of Medicine, Seoul, Korea

10Department of Biomedical Sciences, Dong-A University, Busan, Korea

11Department of Health Sciences, The Graduate School of Dong-A University, Busan, Korea

12Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Corresponding author : Ju-Seog Lee Department of Systems Biology, Unit 1058, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA Tel: +1-713-834-6154, Fax: +1-713-563-4235, E-mail: jlee@mdanderson.org

These authors equally contributed to the writing of this manuscript.

Copyright © 2025 by The Korean Association for the Study of the Liver

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 6,930 Views
  • 49 Download
prev
In the original publication of this paper, the second graph in Figure 4B was erroneously identical with fourth graph in Figure 4B and correct version is provided below. We apologize for any inconvenience that may have been caused.
The original article has been corrected as of 27th February 2025.
Before correction
Figure 4B.
cmh-2024-0333ei1.jpg
After correction
Figure 4B.
cmh-2024-0333ei2.jpg

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

Include:

Erratum to ‘Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial’ [Clin Mol Hepatol 2024;30:807-823]
Clin Mol Hepatol. 2025;31(2):669-670.   Published online February 27, 2025
Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:
Include:
Erratum to ‘Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial’ [Clin Mol Hepatol 2024;30:807-823]
Clin Mol Hepatol. 2025;31(2):669-670.   Published online February 27, 2025
Close
Erratum to ‘Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial’ [Clin Mol Hepatol 2024;30:807-823]
Erratum to ‘Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial’ [Clin Mol Hepatol 2024;30:807-823]